• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzazepines Benzazepines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzazepines

2,3,4,5-Tetrahydro-1H-benzoBazepin-8-amine: A Comprehensive Overview

2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] (CAS No. 518051-96-2) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural and pharmacological properties. This compound belongs to the class of benzazepines, which are known for their diverse biological activities, including antipsychotic, anxiolytic, and antidepressant effects. In this article, we will delve into the chemical structure, synthesis methods, biological activities, and recent research developments surrounding 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine].

Chemical Structure and Properties

The chemical structure of 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] is characterized by a seven-membered azepine ring fused to a benzene ring. The presence of the tetrahydro substitution on the azepine ring imparts significant stability and conformational flexibility to the molecule. The amine group at the 8-position is a key functional group that contributes to its biological activity. The compound has a molecular formula of C₁₃H₁₆N₂ and a molecular weight of 196.27 g/mol. It is typically found as a white crystalline solid with a melting point of approximately 160°C.

Synthesis Methods

The synthesis of 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] can be achieved through various routes. One common method involves the cyclization of an appropriately substituted arylamine with a ketone or aldehyde in the presence of an acid catalyst. For example, the reaction of 3-(aminomethyl)phenylamine with cyclohexanone in the presence of hydrochloric acid can yield 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine]. Another approach involves the reductive amination of a benzyl ketone with an amine followed by cyclization under basic conditions. These synthetic methods provide researchers with flexible pathways to access this important compound.

Biological Activities

2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] has been extensively studied for its potential therapeutic applications due to its ability to modulate various neurotransmitter systems in the brain. One of its primary mechanisms of action is through its interaction with serotonin (5-HT) receptors. Research has shown that this compound exhibits high affinity for 5-HT_1A, 5-HT_2A, and 5-HT₇ receptors, which are implicated in mood regulation and anxiety disorders. Additionally, it has been found to have moderate affinity for dopamine D₂ receptors, suggesting potential antipsychotic properties.

In preclinical studies, 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] has demonstrated significant anxiolytic effects in animal models of anxiety. For instance, it reduced anxiety-like behaviors in mice subjected to elevated plus maze and open field tests without causing sedation or motor impairment. These findings suggest that this compound could be a promising candidate for the development of novel anxiolytic agents with improved safety profiles.

Clinical Trials and Recent Research Developments

The potential therapeutic applications of 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] have led to several clinical trials aimed at evaluating its efficacy and safety in human subjects. A phase II clinical trial conducted by Smith et al. (2021) investigated the use of this compound in patients with generalized anxiety disorder (GAD). The results showed that treatment with 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] led to significant reductions in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale (HAM-A). Notably, the compound was well-tolerated with minimal side effects reported.

In another study by Johnson et al. (2022), researchers explored the potential antidepressant effects of 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine]. The study involved a double-blind placebo-controlled trial in patients with major depressive disorder (MDD). The findings indicated that treatment with this compound resulted in significant improvements in depressive symptoms as assessed by the Montgomery–?sberg Depression Rating Scale (MADRS). These results highlight the broad therapeutic potential of 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine].

Future Directions and Conclusion

The ongoing research into 2,3,4,5-Tetrahydro-1H-benzo[bazepin-8-amine] continues to uncover new insights into its mechanisms of action and therapeutic applications. Future studies may focus on optimizing its pharmacokinetic properties to enhance bioavailability and reduce side effects. Additionally, investigations into its potential use in other psychiatric disorders such as bipolar disorder and schizophrenia are warranted.

In conclusion, 2,3,4,5-TTetrahydro--1H-bbenzo[bbazepin--8-amine) represents a promising molecule with diverse biological activities that warrant further exploration. Its unique chemical structure and favorable pharmacological profile make it an attractive candidate for the development of novel therapeutics targeting mood disorders and other psychiatric conditions.

• 635-46-1(1,2,3,4-Tetrahydroquinoline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)